RKIP’s ability to shift tumor cells into a non-metastatic phenotype by reprogramming kinase networks presents a unique opportunity not only to understand molecular mechanisms of metastatic progression, but also to counteract these mechanisms as a therapeutic strategy. This evidence concerns the gene PEBP1 and neoplasm.